Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:CRSP NASDAQ:HALO NASDAQ:IOVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.28+0.4%$2.42$0.86▼$4.46$555.73M0.4617.68 million shs4.47 million shsCRSPCRISPR Therapeutics$54.83+4.6%$52.34$34.87▼$78.48$5.06B1.741.89 million shs1.73 million shsHALOHalozyme Therapeutics$64.12-1.6%$65.86$47.50▼$82.22$7.72B0.891.31 million shs1.71 million shsIOVAIovance Biotherapeutics$3.62+2.0%$3.81$1.64▼$5.63$1.59B0.6916.81 million shs20.67 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+6.57%-15.93%+34.32%+89.96%CRSPCRISPR Therapeutics0.00%+0.15%+1.28%+7.55%+52.98%HALOHalozyme Therapeutics0.00%+2.40%-0.37%-19.75%-6.94%IOVAIovance Biotherapeutics0.00%+5.65%+2.31%+40.32%+13.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.28+0.4%$2.42$0.86▼$4.46$555.73M0.4617.68 million shs4.47 million shsCRSPCRISPR Therapeutics$54.83+4.6%$52.34$34.87▼$78.48$5.06B1.741.89 million shs1.73 million shsHALOHalozyme Therapeutics$64.12-1.6%$65.86$47.50▼$82.22$7.72B0.891.31 million shs1.71 million shsIOVAIovance Biotherapeutics$3.62+2.0%$3.81$1.64▼$5.63$1.59B0.6916.81 million shs20.67 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+6.57%-15.93%+34.32%+89.96%CRSPCRISPR Therapeutics0.00%+0.15%+1.28%+7.55%+52.98%HALOHalozyme Therapeutics0.00%+2.40%-0.37%-19.75%-6.94%IOVAIovance Biotherapeutics0.00%+5.65%+2.31%+40.32%+13.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.73Moderate Buy$8.44270.11% UpsideCRSPCRISPR Therapeutics 2.56Moderate Buy$65.9420.26% UpsideHALOHalozyme Therapeutics 2.42Hold$79.1123.38% UpsideIOVAIovance Biotherapeutics 2.33Hold$8.63138.26% UpsideCurrent Analyst Ratings BreakdownLatest HALO, IOVA, ALLO, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.005/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.005/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/29/2026HALOHalozyme Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$90.00 ➝ $95.004/20/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026ALLOAllogene Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral4/14/2026ALLOAllogene Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.004/14/2026ALLOAllogene Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/14/2026ALLOAllogene Therapeutics ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$5.00 ➝ $8.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K27,909.48N/AN/A$1.30 per share1.75CRSPCRISPR Therapeutics$3.51M1,506.65N/AN/A$18.81 per share2.91HALOHalozyme Therapeutics$1.40B5.44$4.69 per share13.66$0.42 per share152.67IOVAIovance Biotherapeutics$263.50M6.13N/AN/A$1.76 per share2.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.87N/AN/AN/AN/A-57.07%-41.63%5/13/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%5/11/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.4925.756.990.2722.69%136.12%20.69%5/11/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$1.12N/AN/AN/A-123.92%-50.57%-38.95%N/ALatest HALO, IOVA, ALLO, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19N/AN/AN/A$0.00 millionN/A5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54N/AN/AN/A$358.60 millionN/A5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/12/2026Q4 2025ALLOAllogene Therapeutics-$0.25-$0.17+$0.08-$0.17$0.00 millionN/A2/24/2026Q4 2025IOVAIovance Biotherapeutics-$0.22-$0.18+$0.04-$0.18$81.61 million$86.77 million2/17/2026Investor updateHALOHalozyme Therapeutics$1.92-$0.24-$2.16-$1.20$446.13 million$451.77 million2/13/2026Q4 2025CRSPCRISPR Therapeutics-$1.15-$1.37-$0.22-$1.37$4.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A7.937.93CRSPCRISPR Therapeutics0.3217.9713.32HALOHalozyme Therapeutics43.894.663.66IOVAIovance BiotherapeuticsN/A3.202.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CRSPCRISPR Therapeutics69.20%HALOHalozyme Therapeutics97.79%IOVAIovance Biotherapeutics77.03%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%CRSPCRISPR Therapeutics4.30%HALOHalozyme Therapeutics2.50%IOVAIovance Biotherapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310244.82 million212.50 millionOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableHALOHalozyme Therapeutics390118.47 million115.51 millionOptionableIOVAIovance Biotherapeutics500446.50 million400.51 millionOptionableHALO, IOVA, ALLO, and CRSP HeadlinesRecent News About These CompaniesIOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%May 8 at 12:11 PM | zacks.comChardan Capital Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $14.00May 8 at 8:36 AM | marketbeat.comIovance outlines $350M-$370M 2026 revenue, while guiding Q2 total revenue to $86M-$88MMay 7 at 12:53 AM | seekingalpha.comIovance Biotherapeutics Q1 Earnings Call HighlightsMay 7 at 12:05 AM | marketbeat.comIovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call TranscriptMay 7 at 6:01 PM | seekingalpha.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Time to Sell?May 7 at 4:10 PM | marketbeat.comIovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue EstimatesMay 7 at 9:56 AM | zacks.comIovance Biotherapeutics: Q1 Earnings SnapshotMay 7 at 9:50 AM | sfgate.comA Look At Iovance Biotherapeutics (IOVA) Valuation As Short Interest Eases And Institutions Add ExposureMay 7 at 9:50 AM | finance.yahoo.comIovance slips after Q1 miss amid in-line 2026 outlookMay 7 at 9:50 AM | seekingalpha.comIovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate UpdatesMay 7 at 7:05 AM | globenewswire.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.3% - Still a Buy?May 4, 2026 | marketbeat.comCM Management LLC Decreases Stock Holdings in Iovance Biotherapeutics, Inc. $IOVAMay 3, 2026 | marketbeat.comIovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseApril 30, 2026 | zacks.comIovance Biotherapeutics (IOVA) to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comIovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth FundingApril 29, 2026 | finance.yahoo.comIovance Biotherapeutics: Buy, Because Short-Term Competitor Is OutApril 28, 2026 | seekingalpha.comIovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on ...April 28, 2026 | caledonianrecord.comCIovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026April 27, 2026 | globenewswire.comEquities Analysts Offer Predictions for IOVA Q1 EarningsApril 24, 2026 | marketbeat.comIovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi DrugApril 23, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Alcoa Rebounds as Aluminum Tightens, But a Q1 Miss Tests the RallyBy Jessica Mitacek | April 22, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026The PDT Rule Is On Its Way Out: 5 Stocks That Stand to Benefit the MostBy Ryan Hasson | April 20, 2026HALO, IOVA, ALLO, and CRSP Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$2.28 +0.01 (+0.44%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.31 +0.03 (+1.14%) As of 05/8/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.CRISPR Therapeutics NASDAQ:CRSP$54.83 +2.41 (+4.60%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$54.63 -0.20 (-0.36%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Halozyme Therapeutics NASDAQ:HALO$64.12 -1.07 (-1.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$64.22 +0.10 (+0.15%) As of 05/8/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Iovance Biotherapeutics NASDAQ:IOVA$3.62 +0.07 (+1.97%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.60 -0.02 (-0.55%) As of 05/8/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
